Literature DB >> 23403315

Impaired clearance of apoptotic cells leads to HMGB1 release in the bone marrow of patients with myelodysplastic syndromes and induces TLR4-mediated cytokine production.

Maria Velegraki1, Evaggelia Papakonstanti, Irene Mavroudi, Maria Psyllaki, Christos Tsatsanis, Anastasis Oulas, Ioannis Iliopoulos, Pavlos Katonis, Helen A Papadaki.   

Abstract

Excessive pro-inflammatory cytokine production in the bone marrow has been associated with the pathogenesis of myelodysplastic syndromes. We herein investigated the involvement of toll-like receptors and their endogenous ligands in the induction/maintenance of the inflammatory process in the marrow of patients with myelodysplastic syndromes. We evaluated the expression of toll-like receptors in marrow monocytes of patients (n=27) and healthy controls (n=25) by flow-cytometry and also assessed the activation of the respective signaling using a real-time polymerase chain reaction-based array. We measured the high mobility group box-1 protein, a toll-like receptor-4 ligand, in marrow plasma and long-term bone marrow culture supernatants by an enzyme-linked immunosorbent assay and we performed cross-over experiments using marrow plasma from patients and controls in the presence/absence of a toll-like receptor-4 inhibitor to evaluate the pro-inflammatory cytokine production by chemiluminescence. We assessed the apoptotic cell clearance capacity of patients' macrophages using a fluorescence microscopy-based assay. We found over-expression of toll-like receptor-4 in patients' marrow monocytes compared to that in controls; this over-expression was associated with up-modulation of 53 genes related to the respective signaling. Incubation of patients' monocytes with autologous, but not with normal, marrow plasma resulted in over-production of pro-inflammatory cytokines, an effect that was abrogated by the toll-like receptor-4 inhibitor suggesting that the pro-inflammatory cytokine production in myelodysplastic syndromes is largely mediated through toll-like receptor-4. The levels of high mobility group box-1 protein were increased in patients' marrow plasma and culture supernatants compared to the levels in controls. Patients' macrophages displayed an impaired capacity to engulf apoptotic cells and this defect was associated with excessive release of high mobility group box-1 protein by dying cells. A primary apoptotic cell clearance defect of marrow macrophages in myelodysplastic syndromes may contribute to the induction/maintenance of the inflammatory process through aberrant release of molecules inducing toll-like receptor-4 such as high mobility group box-1 protein.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23403315      PMCID: PMC3729900          DOI: 10.3324/haematol.2012.064642

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  40 in total

Review 1.  Toll-like receptors in the induction of the innate immune response.

Authors:  A Aderem; R J Ulevitch
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

Review 2.  Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator.

Authors:  Helena Erlandsson Harris; Ulf Andersson
Journal:  Eur J Immunol       Date:  2004-06       Impact factor: 5.532

3.  Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.

Authors:  Tony A Navas; Mani Mohindru; Myka Estes; Jing Ying Ma; Lubomir Sokol; Perry Pahanish; Simrit Parmar; Edwin Haghnazari; Li Zhou; Robert Collins; Irene Kerr; Aaron N Nguyen; Yin Xu; Leonidas C Platanias; Alan A List; Linda S Higgins; Amit Verma
Journal:  Blood       Date:  2006-08-29       Impact factor: 22.113

4.  Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis.

Authors:  D Y Zang; R G Goodwin; M R Loken; E Bryant; H J Deeg
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

Review 5.  HMGB1 and RAGE in inflammation and cancer.

Authors:  Gary P Sims; Daniel C Rowe; Svend T Rietdijk; Ronald Herbst; Anthony J Coyle
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

6.  A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome.

Authors:  G M Gersuk; C Beckham; M R Loken; P Kiener; J E Anderson; A Farrand; A B Troutt; J A Ledbetter; H J Deeg
Journal:  Br J Haematol       Date:  1998-10       Impact factor: 6.998

Review 7.  Clearance of apoptotic cells: implications in health and disease.

Authors:  Michael R Elliott; Kodi S Ravichandran
Journal:  J Cell Biol       Date:  2010-06-28       Impact factor: 10.539

8.  Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology.

Authors:  Andrea Pellagatti; Noor Esoof; Fiona Watkins; Cordelia F Langford; David Vetrie; Lisa J Campbell; Carrie Fidler; James D Cavenagh; Helen Eagleton; Peter Gordon; Barrie Woodcock; Beena Pushkaran; Mark Kwan; James S Wainscoat; Jacqueline Boultwood
Journal:  Br J Haematol       Date:  2004-06       Impact factor: 6.998

9.  Impaired granulocytopoiesis in patients with chronic idiopathic neutropenia is associated with increased apoptosis of bone marrow myeloid progenitor cells.

Authors:  Helen A Papadaki; Aristides G Eliopoulos; Theodoros Kosteas; Claudia Gemetzi; Athina Damianaki; Helen Koutala; Juergen Bux; George D Eliopoulos
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

10.  Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration.

Authors:  Davendra Sohal; Andrew Yeatts; Kenny Ye; Andrea Pellagatti; Li Zhou; Perry Pahanish; Yongkai Mo; Tushar Bhagat; John Mariadason; Jacqueline Boultwood; Ari Melnick; John Greally; Amit Verma
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240

View more
  28 in total

1.  The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.

Authors:  Ashley A Basiorka; Kathy L McGraw; Erika A Eksioglu; Xianghong Chen; Joseph Johnson; Ling Zhang; Qing Zhang; Brittany A Irvine; Thomas Cluzeau; David A Sallman; Eric Padron; Rami Komrokji; Lubomir Sokol; Rebecca C Coll; Avril A B Robertson; Matthew A Cooper; John L Cleveland; Luke A O'Neill; Sheng Wei; Alan F List
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

2.  Continuous hemodiafiltration therapy reduces damage of multi-organs by ameliorating of HMGB1/TLR4/NFκB in a dog sepsis model.

Authors:  Jing Sun; Shaolan Shi; Qun Wang; Kezhou Yu; Rong Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  Loss of Toll-like receptor 2 results in accelerated leukemogenesis in the NUP98-HOXD13 mouse model of MDS.

Authors:  Darlene A Monlish; Sima T Bhatt; Eric J Duncavage; Zev J Greenberg; John L Keller; Molly P Romine; Wei Yang; Peter D Aplan; Matthew J Walter; Laura G Schuettpelz
Journal:  Blood       Date:  2018-01-22       Impact factor: 22.113

4.  Targeting High Mobility Group Box-1 (HMGB1) Promotes Cell Death in Myelodysplastic Syndrome.

Authors:  Angel Y F Kam; Sadhna O Piryani; Chad M McCall; Hee Su Park; David A Rizzieri; Phuong L Doan
Journal:  Clin Cancer Res       Date:  2019-04-05       Impact factor: 12.531

Review 5.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

6.  The protective effect of uric acid in reducing TLR4/NF-κB activation through the inhibition of HMGB1 acetylation in a model of ischemia-reperfusion injury in vitro.

Authors:  Guan-Mei Cheng; Ruo-Lu Wang; Bin Zhang; Xiao-Ying Deng
Journal:  Mol Biol Rep       Date:  2020-02-24       Impact factor: 2.316

7.  Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia.

Authors:  Li Jia; Andrew Clear; Feng-Ting Liu; Janet Matthews; Nadiha Uddin; Aine McCarthy; Elena Hoxha; Catherine Durance; Sameena Iqbal; John G Gribben
Journal:  Blood       Date:  2014-01-24       Impact factor: 22.113

Review 8.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

9.  Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.

Authors:  Ganesan Keerthivasan; Yang Mei; Baobing Zhao; Ling Zhang; Chad E Harris; Juehua Gao; Ashley A Basiorka; Matthew J Schipma; James McElherne; Jing Yang; Amit K Verma; Andrea Pellagatti; Jacqueline Boultwood; Alan F List; David A Williams; Peng Ji
Journal:  Blood       Date:  2014-06-02       Impact factor: 22.113

Review 10.  Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.

Authors:  Kathryn S Ivy; P Brent Ferrell
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.